Search

Influenza Gut–Lung Axis Infection Models for Oral Live Biotherapeutic Evaluation

Evaluate how oral live biotherapeutic candidates modulate respiratory immunity in influenza challenge models through integrated lung immune, microbiome, and metabolite readouts.

Oral live biotherapeutic candidates intended for respiratory immune modulation require study designs that connect gut changes with lung outcomes. Creative Biolabs offers influenza gut–lung axis infection models that combine oral intervention, respiratory challenge, pulmonary immune readouts, and gut microbiome/metabolite profiling to support mechanism-oriented evaluation of LBP candidates.

Bridging the Gap in Oral LBP Respiratory Evaluation

While researchers increasingly recognize the gut-lung axis as a critical pathway for respiratory defense, developers of oral live biotherapeutics face specific translational hurdles when validating these concepts *in vivo*:
  • Lack of Verified Efficacy Links: Oral LBP effects on lung antiviral immunity are difficult to verify in conventional efficacy models without properly linked systemic data spanning both anatomical sites.
  • Disconnected Readouts: Gut microbiome changes are often measured independently without matched pulmonary immune readouts, leaving the mechanism unverified.
  • Missing Correlation Data: Sponsors need integrated evidence linking oral dosing, gut microbial changes, and respiratory immune outcomes to make informed downstream clinical decisions.

Our customizable gut-lung axis infection models address these challenges directly, providing an integrated framework to help characterize the systemic immunomodulatory mechanisms of your LBP candidates.

Mechanism-Oriented Evaluation Services

We execute highly customizable preclinical study designs offering specific readout packages to ensure your candidate's mechanism of action is thoroughly characterized.

Influenza Infection Model Setup and Oral Dosing Strategy

Our platform utilizes specific respiratory viruses (e.g., Influenza A virus strains such as PR8). We support customizable oral administration strategies, enabling direct comparison of prophylactic vs. therapeutic regimens. Options include tracking strain viability *in vivo* and optimizing the dosing window before or during the viral challenge phase to best match your intended clinical use.

Pulmonary Immune and Antiviral Readouts

We quantify localized lung immune responses using bronchoalveolar lavage fluid (BALF) and tissue samples. The readout package is highly adaptable and can include flow cytometry for specific inflammatory cell subsets (macrophages, neutrophils, T-cells), lung viral load quantification, detailed histopathology scoring, and targeted assessment of critical cytokines and IFN-stimulated genes (ISGs).

Gut Microbiome and Metabolite Profiling

To establish the essential mechanistic link, we monitor gastrointestinal changes through targeted strain tracking, 16S rRNA sequencing, or shotgun metagenomics on collected fecal matter. Additionally, we provide targeted metabolomic options (e.g., LC-MS/MS) to quantify fecal and serum metabolites, such as short-chain fatty acids (SCFAs), supporting the evaluation of systemic mediators.

Integrated Mechanism-Oriented Data Interpretation

We help sponsors go beyond isolated datasets by offering integrated interpretation services. This involves generating correlation networks and multivariate analyses that evaluate the relationship between specific gut taxa or systemic metabolite fluctuations and corresponding protective pulmonary immune endpoints, providing a cohesive narrative for your candidate.

Study Dimension Representative Readouts Optional Methods
Clinical Physiology Survival rate, body weight tracking, clinical scoring. In vivo daily monitoring
Pulmonary Virology & Pathology Lung viral titer, lung index, histopathological lesion scoring. Plaque assay, qPCR, Tissue Histology
Immune Cell Infiltration Quantification of alveolar macrophages, neutrophils, T cell subsets in BALF/Lung. Multi-color Flow Cytometry
Cytokine & IFN Cascades IFN-α, IFN-β, IFN-γ, IL-1β, IL-6, TNF-α, antiviral gene expression. Multiplex ELISA, RT-qPCR, RNA-Seq
Gastrointestinal Environment Microbial diversity, taxonomic shifts, targeted SCFA concentrations. 16S Sequencing, Metagenomics, LC-MS/MS
Gut–Lung Association Analysis Correlations between lung immune endpoints and gut microbiome/metabolites. Multivariate analysis, correlation network, pathway interpretation

Study Deliverables for Influenza Gut–Lung Axis Evaluation

We deliver structured, actionable data packages designed to support your team's internal decision-making and downstream translational development.

Study Report

Complete documentation with detailed methodology, statistical analyses, and interpreted results.

Processed Datasets

Organized raw and processed files including flow cytometry FCS outputs, sequencing reads, and metabolite metrics.

Endpoint Recommendation

Targeted recommendation package based on findings to support subsequent preclinical or clinical study designs.

Mechanism Summary

Correlation summary bridging identified gut microbial signatures to systemic and localized pulmonary markers.

Influenza Gut–Lung Axis Study Workflow

A synchronized timeline designed to ensure precision at every temporal sampling point.

1

Consultation & Design

Define LBP strain parameters, viral challenge titers, and customize the study dimension panels.

2

Oral Dosing Window

Baseline fecal samples collected, followed by scheduled oral administration (prophylactic or therapeutic strategy).

3

Intranasal Challenge

Standardized inoculation with Influenza virus while continuing scheduled clinical monitoring and dosing.

4

Sample Collection

Scheduled harvest of BALF, lung tissue, blood, and feces at precise post-infection temporal endpoints.

5

Data Integration

Parallel execution of immune, microbiome, and metabolite readouts leading to integrated correlation interpretation.

Advantage of Our Modeling Strategy

Aligned Oral Interventions

Oral dosing regimens specifically aligned with respiratory infection model timelines to accurately reflect systemic kinetics.

Integrated Readouts

Paired pulmonary and gut evaluations from the same study cohort minimize experimental variation and strengthen correlation reliability.

Customizable Endpoint Panels

Highly flexible selection of immune cells, cytokines, ISGs, and microbial targets oriented toward your candidate's hypothesized mechanism.

Published Data: Preclinical Validation of Microbiome-Mediated Respiratory Protection

Oral administration of L. paracasei enhances host protection against influenza infection. (Creative Biolabs Authorized)

Fig.1 Oral administration of L. paracasei MI29 protects the host from influenza infection.1,3

Recent translational studies critically emphasize the therapeutic potential of specific probiotic strains to modulate respiratory immunity via the gut-lung axis. Contemporary research clearly demonstrates that the oral administration of certain Lactobacillus paracasei strains significantly augments host survival and drastically diminishes pulmonary viral titers following lethal influenza virus challenge.

This robust protection is strongly correlated with the beneficial modulation of gut microbiota composition and the systemic enhancement of pulmonary immune responses. Key mechanistic observations include the precise regulation of inflammatory cytokines, the activation of local interferon pathways, and the recruitment of essential alveolar phagocytes.

Creative Biolabs draws upon these experimental paradigms to help design custom efficacy studies for your oral LBP candidates, supporting mechanism-oriented evaluation and providing a robust preclinical dataset for your downstream development.

Frequently Asked Questions

Yes, our study designs are highly customizable. We can configure parallel cohorts to evaluate both prophylactic (pre-infection) and therapeutic (post-infection) oral dosing regimens. This comparative approach helps characterize the optimal intervention window and enables mechanism-oriented evaluation of your LBP candidate under different administration strategies.

To enable integrated mechanism-oriented data interpretation, we recommend a paired sampling strategy. This typically includes bronchoalveolar lavage fluid (BALF) and lung tissues for immune and viral readouts, alongside matched fecal pellets and serum collected at scheduled temporal endpoints. This comprehensive sampling allows us to link gastrointestinal microbiome shifts and systemic metabolites with localized pulmonary responses.

Yes, combining these endpoints provides a robust evaluation package. We routinely integrate lung viral load quantification (via plaque assay or qPCR) and detailed histopathology scoring alongside advanced immune readouts such as flow cytometry and cytokine profiling. This ensures a comprehensive characterization of both the infection severity and the host's immune response.

Marker selection is tailored to the proposed mechanism of action of your specific LBP candidate. We typically recommend a baseline panel covering key innate and adaptive immune mediators (e.g., IL-1β, IL-6, TNF-α, IFN-γ) and critical antiviral Type I/III interferons. Based on your initial in vitro data or specific target pathways, we can customize the readout package to include specific IFN-stimulated genes (ISGs) or specialized T-cell subset markers.

Other Resources

Creative Biolabs' Live Biotherapeutics - Brochure (Creative Biolabs Original)

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic Strain Products for NGP Research - Brochure (Creative Biolabs Original)

Probiotic Strain Products for NGP Research - Brochure

Custom Small-scale Probiotic Production - Brochure (Creative Biolabs Original)

Custom Small-scale Probiotic Production - Brochure

Live Biotherapeutics - Creative Biolabs - Video (Creative Biolabs Original)

Live Biotherapeutics - Creative Biolabs - Video

References

  1. Kim, Seungil, et al. "Newly isolated Lactobacillus paracasei strain modulates lung immunity and improves the capacity to cope with influenza virus infection." Microbiome 11.1 (2023): 260. https://doi.org/10.1186/s40168-023-01687-8
  2. Sencio, Valentin, Marina Gomes Machado, and Francois Trottein. "The lung–gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes." Mucosal Immunology 14.2 (2021): 296-304. https://doi.org/10.1038/s41385-020-00361-8
  3. Distributed under Open Access license CC BY 4.0, without modification.
Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Creative Biolabs-Live Biotherapeutics


ISO 9001 Certified - Creative Biolabs Quality Management System.
Contact us
Solutions

Copyright © 2026 Creative Biolabs. All Rights Reserved.

Inquiry Basket